IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
IceCure Medical Ltd. (Nasdaq: ICCM) said Adventist Health Glendale in California signed an agreement and received IRB approval to become the first U.S. site enrolling patients in its post-marketing ChoICE study for ProSense cryoablation in low-risk breast cancer. The study will enroll up to 400 patients across multiple sites to generate real-world data after FDA marketing authorization in Oct. 2025.
How this was made
The 30-second read
Why it matters
The announcement that Adventist Health Glendale is the first U.S. site able to enroll patients (agreement signed and IRB approved) is a tangible step in trial execution. It supports the company’s broader commercialization narrative by enabling dual-purpose sites that both enroll and treat eligible patients outside the trial.
Market read
Operational progress on a post-marketing study can influence investor perception of execution and commercialization momentum, but the release lacks outcome data.
What to watch
Traders may be underweighting that the study targets patients aged 70+ with low-risk tumors, so addressable volume and reimbursement dynamics could still limit near-term impact.
Background
IceCure’s ProSense cryoablation received FDA marketing authorization in October 2025, and the ChoICE post-marketing study is intended to generate real-world data for low-risk breast cancer patients on endocrine therapy.
Ticker impact
IceCure says Adventist Health Glendale became the first U.S. site with IRB approval to enroll patients in its post-marketing ChoICE study for ProSense.
Near-term sentiment tailwind for ICCM tied to trial execution progress; magnitude likely modest absent enrollment numbers or results.
The release is a specific operational update (first enrolling site, IRB approval) but does not provide new efficacy/safety outcomes, revenue guidance, or regulatory changes beyond the already-mentioned FDA authorization.
Market effects
Reinforces demand for minimally invasive cryoablation and the use of real-world evidence to expand adoption in breast cancer.
U.S. clinical execution progress may improve confidence in U.S. rollout of ProSense.
Primarily U.S.-focused, but successful real-world data generation can support broader international adoption narratives.
Counterpoint
First-site enrollment does not guarantee faster overall enrollment or improved commercial uptake; it may be more execution signaling than demand proof.
Key entities
- companyIceCure Medical Ltd.
Developer and marketer of liquid-nitrogen-based cryoablation systems, including ProSense.
- clinical_siteAdventist Health Glendale
First U.S. clinical site with agreement and IRB approval to enroll patients in the ChoICE study.
- productProSense
IceCure’s cryoablation system cleared by the FDA for local treatment in specified low-risk breast cancer patients aged 70+.
- clinical_studyChoICE Study
Post-marketing real-world study evaluating ProSense with endocrine therapy for low-risk, early-stage breast cancer in patients aged 70+.
